1. Worsening membranous nephropathy in a patient with GIST treated with sunitinib
- Author
-
Shahrzad Zonoozi, Teitelbaum Ursina, Matthew B. Palmer, and Abdallah S. Geara
- Subjects
medicine.medical_specialty ,Thrombotic microangiopathy ,Proteinuria ,Nephrotic Syndrome ,GiST ,Sunitinib ,business.industry ,Gastrointestinal Stromal Tumors ,General Medicine ,medicine.disease ,Gastroenterology ,Glomerulonephritis, Membranous ,Membranous nephropathy ,Internal medicine ,medicine ,Humans ,Rituximab ,Hypoalbuminemia ,medicine.symptom ,business ,Nephrotic syndrome ,medicine.drug ,Aged ,Autoantibodies - Abstract
Tyrosine kinase inhibitors (TKI) are anticancer agents widely used for a variety of malignancies including gastrointestinal stromal tumours (GIST). Although generally well-tolerated, TKIs have been associated with a number of adverse events including hypertension, proteinuria and nephrotic syndrome. We present the case of a 70-year-old patient with metastatic GIST on long-standing sunitinib who developed hypertension, oedema and hypoalbuminemia with a rising serum creatinine and was found to have nephrotic syndrome. Workup revealed elevated antiphospholipase A2 receptor (PLA2R) antibody IgG titres and a kidney biopsy confirmed PLA2R-positive membranous nephropathy without findings of thrombotic microangiopathy. Cessation of sunitinib led to reduction in anti-PLA2R antibody IgG titres while resumption, due to concern for cancer progression, led to worsening symptoms. Treatment with rituximab led to undetectable anti-PLA2R IgG titres. We highlight the importance of maintaining a systematic approach for evaluating nephrotic syndrome and provide a case showing that TKIs can exacerbate underlying nephrotic syndrome.
- Published
- 2023